EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evolutionary rate covariation is pervasive between glycosylation pathways and points to potential disease modifiers

Holly J Thorpe iD, Raghavendran Partha iD, Jordan Little iD, Nathan L Clark, Clement Y Chow iD

PLOS Genetics · 2024

DOI: 10.1371/journal.pgen.1011406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Genetics, 2024. Verfasst von Holly J Thorpe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah, United States of America. Hauptthemen laut MEDLINE: Congenital Disorders of Glycosylation, Evolution, Molecular. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, NIGMS NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in glycosylation pathways, such as N-linked glycosylation, O-linked glycosylation, and GPI anchor synthesis, lead to Congenital Disorders of Glycosylation (CDG). CDG typically present with seizures, hypotonia, and developmental delay but display large clinical variability with symptoms affecting every system in the body. This variability suggests modifier genes might influence the phenotypes. Because of the similar physiology and clinical symptoms, there are likely common genetic modifiers between CDG. Here, we use evolution as a tool to identify common modifiers between CDG and glycosylation genes. Protein glycosylation is evolutionarily conserved from yeast to mammals. Evolutionary rate covariation (ERC) identifies proteins with similar evolutionary rates that indicate shared biological functions and pathways. Using ERC, we identified strong evolutionary rate signatures between proteins in the same and different glycosylation pathways. Genome-wide analysis of proteins showing significant ERC with GPI anchor synthesis proteins revealed strong signatures with ncRNA modification proteins and DNA repair proteins. We also identified strong patterns of ERC based on cellular sub-localization of the GPI anchor synthesis enzymes. Functional testing of the highest scoring candidates validated genetic interactions and identified novel genetic modifiers of CDG genes. ERC analysis of disease genes and biological pathways allows for rapid prioritization of potential genetic modifiers, which can provide a better understanding of disease pathophysiology and novel therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Congenital Disorders of GlycosylationEvolution, MolecularGlycosylationHumansAnimalsMutationGlycosylphosphatidylinositolsPhenotype

Substanzen

Glycosylphosphatidylinositols

Autor:innen und Institutionen

  • Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
  • Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.

ORCID-Profile: Holly J Thorpe, Raghavendran Partha, Jordan Little, Clement Y Chow

Förderung

  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • National Human Genome Research Institute
  • National Institute of General Medical Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Thorpe, H. J., Partha, R., Little, J., Clark, N. L., & Chow, C. Y. (2024). Evolutionary rate covariation is pervasive between glycosylation pathways and points to potential disease modifiers. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1011406

Vancouver

Thorpe HJ, Partha R, Little J, Clark NL, Chow CY. Evolutionary rate covariation is pervasive between glycosylation pathways and points to potential disease modifiers. PLOS Genetics. 2024. doi:10.1371/journal.pgen.1011406

BibTeX
@article{Thorpe2024,
  author = {Thorpe, Holly J and Partha, Raghavendran and Little, Jordan and Clark, Nathan L and Chow, Clement Y},
  title = {Evolutionary rate covariation is pervasive between glycosylation pathways and points to potential disease modifiers},
  journal = {PLOS Genetics},
  year = {2024},
  doi = {10.1371/journal.pgen.1011406}
}
Kostenlos starten →